TITLE

FDA approves kallikrein inhibitor to treat hereditary angioedema

AUTHOR(S)
Thompson, Cheryl A.
PUB. DATE
January 2010
SOURCE
American Journal of Health-System Pharmacy;1/15/2010, Vol. 67 Issue 2, p93
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports that the U.S. Food and Drug Administration (FDA) has approved the marketing of Dyax Corp.'s injection targeting kallikrein inhibitor for the treatment of hereditary angioedema. Ecallantide, a prime component of the injection, binds to plasma kallikrein and blocks its binding site, resulting in less production of bradykinin, the primary mediator of hereditary angioedema attacks, which can be fatal.
ACCESSION #
47922156

 

Related Articles

  • FDA Complete Response Delays Dyax HAE Drug. Harris, Glenn // BioWorld Today;3/30/2009, Vol. 20 Issue 59, p1 

    The article reports that the approval of DX-88, a drug for acute attacks of hereditary angioedema (HAE) from Dyax Corp., will be delayed. The Food and Drug Administration is requesting the company to prove a risk evaluation and mitigation strategy and more information relating to chemistry,...

  • Dyax Pushes Toward Front of Race for HAE Therapy. Hollingsworth, Catherine // BioWorld Today;9/25/2008, Vol. 19 Issue 187, p1 

    This article reports on a biologics license application filed by Dyax Corp. with the Food and Drug Administration (FDA) for its potential treatment for hereditary angioedema (HAE) in 2008. Dyax sees the subcutaneous administration of DX-88 (ecallantide) as a potential advantage over the...

  • FDA Panel Narrowly Backs Dyax's HAE Drug Kalbitor. Young, Donna // BioWorld Today;2/5/2009, Vol. 20 Issue 23, p1 

    This article reveals that a U.S. Food and Drugs Administration (FDA) panel has backed the approval of Dyax Corporation's Kalbitor to treat acute attacks of hereditary angioedema (HAE) in spite of the drug's potential to cause severe allergic reations and a lack of robust study data. According to...

  • Dyax's Kalbitor OK'd; Berinert Could Be Hurt in Acute HAE. Boggs, Jennifer // BioWorld Today;12/3/2009, Vol. 20 Issue 232, p1 

    The article reports that the Food and Drug Administration (FDA) in the U.S. has given approval to Dyax Corp. for Kalbitor, an eccalantide drug. Expected to be launched in the first quarter of 2010, the drug is in direct competition against Berinert in the market for hereditary angioedema (HAE)...

  • Dyax's Kalbitor OK'd; Berinert Faces Challenge.  // Bioworld Week;12/7/2009, Vol. 17 Issue 49, p4 

    The article reports that Dyax Corp. is planning to launch a drug Kalbitor in 2010 to fight against diseases like the hereditary angioedema (HAE) after the approval of U.S. Food & Drug Administration (FDA). The drug will be placed against the latest approved drug Clinhibitor Berinert in the...

  • FDA Complete Response Delays Dyax HAE Drug.  // Bioworld Week;4/6/2009, Vol. 17 Issue 14, p2 

    The article reports on the decision of the Food and Drug Administration (FDA) to delay the approval of Dyax Corp.'s treatment for acute attacks of hereditary angioedema in the U.S. A complete response letter for DX-88 (ecallantide), requesting a risk evaluation and mitigation strategy was issued...

  • Kalbitor for HAE attacks.  // Monthly Prescribing Reference;Jan2010, Vol. 26 Issue 1, pA12 

    The article reports on the approval of the drug Kalbitor from Dyax Corp. as treatment for acute attacks of hereditary angioedema (HAE) by the U.S. Food and Drug Administration (FDA).

  • Still No Winner in Acute HAE; FDA Wants New Cinryze Trial. Boggs, Jennifer // BioWorld Today;6/5/2009, Vol. 20 Issue 107, p1 

    The article reports that the U.S. Food and Drug Administration (FDA) asked ViroPharma Inc. to conduct a new trial for Cinryze for the treatment of acute hereditary angioedema (HAE) attacks. FDA claimed that the previous placebo-controlled Phase III trial of the drug lack robustness in data. The...

  • Cinryze Receives FDA Approval for Prevention of Angioedema.  // BioPharm International;Dec2008, Vol. 21 Issue 12, p16 

    The article reports on the U.S. Food and Drug Administration's (DFA) approval of the Cinryze (C1 inhibitor) developed by Lev Pharmaceuticals Inc. in New York City. The inhibitor is intended for routine prophylaxis particularly preventing the angioedema attacks in adolescent and adult patients...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics